Onconova Appoints James J. Marino, Esq. to Board of Directors
08 juil. 2015 08h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., July 8, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. to Present Corporate Update at the Cantor Fitzgerald Healthcare Conference
01 juil. 2015 16h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., July 1, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX) a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Tuesday, June 30 in New York City
23 juin 2015 08h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., June 23, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Presents Patient Selection Criteria and Intermediate Clinical Endpoints for Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at EHA Annual Meeting
15 juin 2015 08h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., June 15, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Presents Clinical Data on Rigosertib in Higher-Risk Myelodysplastic Syndromes (HR-MDS) at the 2015 ASCO Annual Meeting
01 juin 2015 08h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., June 1, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2015 Financial Results
14 mai 2015 16h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., May 14, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Announces Multiple Rigosertib Clinical Data Presentations at the 2015 ASCO Annual Meeting
13 mai 2015 17h15 HE
|
Onconova Therapeutics
NEWTOWN, Pa., May 13, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Presenting Nine Abstracts Related to Rigosertib at the 13th International Symposium on Myelodysplastic Syndromes (MDS)
01 mai 2015 08h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., May 1, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Highlights Rigosertib and Early-stage Programs at the 2015 American Association of Cancer Research (AACR) Annual Meeting
21 avr. 2015 16h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., April 21, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...
Onconova Therapeutics, Inc. Submits Pivotal Clinical Trial Protocol for IV Rigosertib in Higher-Risk Myelodysplastic Syndromes to FDA and EMA
20 avr. 2015 08h01 HE
|
Onconova Therapeutics
NEWTOWN, Pa., April 20, 2015 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat...